Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight
  • Published:

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro

Leukemia volume 18, pages 1332–1339 (2004)Cite this article

Abstract

The ABL tyrosine kinase inhibitor imatinib mesylate is highly effective in the treatment of CML and is increasingly used in the stem cell transplantation (SCT) setting. Since ABL-dependent intracellular signaling molecules are involved in T-cell activation, imatinib may affect T-cell responses in vivo, thus affecting T-cell function in CML patients, disrupting immune reconstitution after allogeneic SCT and/or impeding the graft-versus-leukemia effect. Here we demonstrate that imatinib inhibits PHA-induced proliferation of normal peripheral blood mononuclear cells at in vitro concentrations (1–5 μmol/l) representative of the pharmacological doses used therapeutically in vivo. The effect is not dependent on antigen-presenting cells because CD3/CD28-induced T-cell stimulation was similarly inhibited by imatinib. Dose-dependent inhibition of the proliferative response of purified CD8+ and CD4+ T lymphocytes to anti-CD3/CD28 was similarly observed and associated with reduction in IFN-γ production. The inhibitory effect could not be ascribed to an increased rate of apoptosis but the expression of activation markers on CD3+ T cells was significantly reduced in the presence of imatinib (1–5 μmol/L). Inhibition of T-cell proliferation was reversible after removal of the drug from the cultures. Thus, imatinib inhibits T-cell proliferation in vitro, an effect that is APC-independent, reversible, and does not involve apoptosis induction.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

References

  1. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–1042.

    Article  CAS  PubMed  Google Scholar 

  2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.

    Article  CAS  PubMed  Google Scholar 

  3. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.

    Article  CAS  PubMed  Google Scholar 

  4. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539.

    Article  CAS  PubMed  Google Scholar 

  5. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–1937.

    Article  CAS  PubMed  Google Scholar 

  6. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566.

    Article  CAS  PubMed  Google Scholar 

  7. Deininger MW, Goldman JM, Lydon N, Melo JV . The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691–3698.

    CAS  PubMed  Google Scholar 

  8. Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997; 23: 380–394.

    Article  CAS  PubMed  Google Scholar 

  9. Druker BJ, Lydon NB . Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105: 3–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139–145.

    CAS  PubMed  Google Scholar 

  11. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ . Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925–932.

    CAS  PubMed  Google Scholar 

  12. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481–487.

    Article  CAS  PubMed  Google Scholar 

  13. Okuda K, Weisberg E, Gilliland DG, Griffin JD . ARG tyrosine kinase activity is inhibited by STI571. Blood 2001; 97: 2440–2448.

    Article  CAS  PubMed  Google Scholar 

  14. Takahashi N, Miura I, Saitoh K, Miura AB . Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood 1998; 92: 4758–4763.

    CAS  PubMed  Google Scholar 

  15. Garicochea B, Chase A, Lazaridou A, Goldman JM . T lymphocytes in chronic myelogenous leukaemia (CML): no evidence of the BCR/ABL fusion gene detected by fluorescence in situ hybridization in 14 patients. Leukemia 1994; 8: 1197–1201.

    CAS  PubMed  Google Scholar 

  16. Cho EK, Heo DS, Seol JG, Seo EJ, Chi HS, Kim ES et al. Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia. Br J Haematol 2000; 111: 216–222.

    Article  CAS  PubMed  Google Scholar 

  17. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R . Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002; 99: 3792–3800.

    Article  CAS  PubMed  Google Scholar 

  18. Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, Mulligan RC . Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 1991; 65: 1153–1163.

    Article  CAS  PubMed  Google Scholar 

  19. Schwartzberg PL, Stall AM, Hardin JD, Bowdish KS, Humaran T, Boast S et al. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell 1991; 65: 1165–1175.

    Article  CAS  PubMed  Google Scholar 

  20. Baskaynak G, Kreuzer KA, Schwarz M, Zuber J, Audring H, Riess H et al. Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment. Eur J Haematol 2003; 70: 231–234.

    Article  PubMed  Google Scholar 

  21. Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J et al. Development of Varicella–Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 2003; 9: 976–980.

    CAS  PubMed  Google Scholar 

  22. Jiang S, Camara N, Lombardi G, Lechler RI . Induction of allopeptide-specific human CD4+CD25+ regulatory T cells ex-vivo. Blood 2003; 102: 2180–2186.

    Article  CAS  PubMed  Google Scholar 

  23. Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD et al. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 2001; 98: 2736–2744.

    Article  CAS  PubMed  Google Scholar 

  24. Ferraresso M, Rigotti P, Stepkowski SM, Chou TC, Kahan BD . Immunosuppressive effects of defibrotide. Transplantation 1993; 56: 928–933.

    Article  CAS  PubMed  Google Scholar 

  25. Ferron GM, Jusko WJ . Species- and gender-related differences in cyclosporine/prednisolone/sirolimus interactions in whole blood lymphocyte proliferation assays. J Pharmacol Exp Ther 1998; 286: 191–200.

    CAS  PubMed  Google Scholar 

  26. Kahan BD, Gibbons S, Tejpal N, Stepkowski SM, Chou TC . Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991; 51: 232–239.

    Article  CAS  PubMed  Google Scholar 

  27. Jordan WJ, Ritter MA . Optimal analysis of composite cytokine responses during alloreactivity. J Immunol Methods 2002; 260: 1–14.

    Article  CAS  PubMed  Google Scholar 

  28. Tsuda H, Yamasaki H . Type I and type II T cell profiles in chronic myelogenous leukemia. Acta Haematol 2000; 103: 96–101.

    Article  CAS  PubMed  Google Scholar 

  29. Guarini A, Breccia M, Montefusco E, Petti MC, Zepparoni A, Vitale A et al. Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission. Br J Haematol 2001; 113: 136–142.

    Article  CAS  PubMed  Google Scholar 

  30. Aswald JM, Lipton JH, Messner HA . Intracellular cytokine analysis of interferon-gamma in T cells of patients with chronic myeloid leukemia. Cytokines Cell Mol Ther 2002; 7: 75–82.

    Article  CAS  PubMed  Google Scholar 

  31. Reuben JM, Lee BN, Johnson H, Fritsche H, Kantarjian HM, Talpaz M . Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha. Clin Cancer Res 2000; 6: 1671–1677.

    CAS  PubMed  Google Scholar 

  32. Pawelec G, Rehbein A, Schlotz E, da Silva P . Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro. Cancer Immunol Immunother 1996; 42: 193–199.

    Article  CAS  PubMed  Google Scholar 

  33. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A . Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683–765.

    Article  CAS  PubMed  Google Scholar 

  34. Dong R, Cwynarski K, Entwistle A, Marelli-Berg F, Dazzi F, Simpson E et al. Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood 2003; 101: 3560–3567.

    Article  CAS  PubMed  Google Scholar 

  35. Kiani A, Habermann I, Schake K, Neubauer A, Rogge L, Ehninger G . Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib. Haematologica 2003; 88: 754–761.

    PubMed  Google Scholar 

  36. Appel S, Boehmler AM, Grunebach F, Muller MR, Rupf A, Weck MM et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004; 103: 538–544.

    Article  CAS  PubMed  Google Scholar 

  37. Steegmann JL, Moreno G, Alaez C, Osorio S, Granda A, de la Camara R et al. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica 2003; 88: 762–768.

    CAS  PubMed  Google Scholar 

  38. Mohty M, Jourdan E, Ben Mami N, Vey N, Damaj G, Blaise D et al. Imatinib and plasmacytoid dendritic cell function in chronic myeloid leukemia patients. Blood 2004, (Epub ahead of print).

  39. Jonas D, Lubbert M, Kawasaki ES, Henke M, Bross KJ, Mertelsmann R et al. Clonal analysis of bcr-abl rearrangement in T lymphocytes from patients with chronic myelogenous leukemia. Blood 1992; 79: 1017–1023.

    CAS  PubMed  Google Scholar 

  40. Auffermann-Gretzinger S, Lossos IS, Vayntrub TA, Leong W, Grumet FC, Blume KG et al. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood 2002; 99: 1442–1448.

    Article  CAS  PubMed  Google Scholar 

  41. Wassmann B, Pfeifer H, Scheuring U, Klein SA, Gokbuget N, Binckebanck A et al. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia 2002; 16: 2358–2365.

    Article  CAS  PubMed  Google Scholar 

  42. Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100: 1590–1595.

    CAS  PubMed  Google Scholar 

  43. Olavarria E, Craddock C, Dazzi F, Marin D, Marktel S, Apperley JF et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002; 99: 3861–3862.

    Article  CAS  PubMed  Google Scholar 

  44. Wassmann B, Scheuring U, Thiede C, Pfeifer H, Bornhauser M, Griesinger F et al. Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2003; 31: 611–614.

    Article  CAS  PubMed  Google Scholar 

  45. Hehlmann R, Hochhaus A, Kolb HJ, Hasford J, Gratwohl A, Heimpel H et al. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 1999; 94: 3668–3677.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, Division of Medicine, Faculty of Medicine, Imperial College at Hammersmith Hospital, London, UK

    K Cwynarski, R Laylor, E Macchiarulo, G Lombardi, J V Melo & F Dazzi

  2. Department of Haematology, Division of Investigative Science, Faculty of Medicine, Imperial College at Hammersmith Hospital, London, UK

    K Cwynarski, J Goldman & F Dazzi

Authors
  1. K Cwynarski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Laylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Macchiarulo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Lombardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J V Melo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F Dazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F Dazzi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cwynarski, K., Laylor, R., Macchiarulo, E. et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 18, 1332–1339 (2004). https://doi.org/10.1038/sj.leu.2403401

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403401

Keywords

This article is cited by

Search

Advanced search

Quick links